EARLY Registry – Real Life Evidence (Newly diagnosed Hypertensives and Young Hypertensives). The previous article provided the clinical overview of azilsartan and demonstrates the safety and efficacy of azilsartan in comparison with other sartans. Click here to read more. In a prospective, observational, national, multicentre registry (EARLY) the efficacy and safety of Azilsartan was monitored for 12 months in comparison to ACE inhibitors (mostly Ramipril).
The objective of the study was to evaluate Efficacy: Achievement of target BP <140/90 mmHg Safety profile A total of 3849 patients were enrolled in the study and 2809 (73%) were treated with azilsartan medoxomil 40 & 80 mg and rest 1040 (27%) with ACE-inhibitors mainly ramipril 10 mg (889 patients, 85.5 %). Azilsartan was significantly superior in reducing the mean BP (both SBP/DBP) when compared to Ramipril (p<0.001). The proportion…
